Vistusertib - CISMeF

Preferred Label : Vistusertib;

NCIt synonyms : Benzamide, 3-(2,4-Bis((3S)-3-methyl-4-morpholinyl)pyrido(2,3-d)pyrimidin-7-yl)-N-methyl-;

NCIt definition : An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.;

UNII : 0BSC3P4H5X;

InChIKey : JUSFANSTBFGBAF-IRXDYDNUSA-N;

CAS number : 1009298-59-2;

Molecule name : AZD-2014; AZD 2014;

Détails

Origin ID

C88329;

UMLS CUI

C4287801;

Automatic exact mappings (from CISMeF team)
- vistusertib [MeSH concept]
Currated CISMeF NLP mapping
- vistusertib [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- vistusertib [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Serine/Threonine-Protein Kinase mTOR [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients